Se encuentra usted aquí
Articulos sobre fondos
The more idiosyncratic your human and nonportfolio financial capital, the more 'vanilla' your portfolio should be.
The company’s growth has been impressive, but we worry about approaching headwinds.
These fixed-income funds could be well positioned to outperform if investors abandon riskier assets in favor of higher-quality fare.
An idea whose time has come--and gone.
The odds may be better for small-cap managers, but they're still long.
Our top managers are turning over more rocks in search for buried treasure.
But industry pressures continue to dog the firm.
Six good funds are hit with outflows, but three small good funds are seeing inflows.
Key players in the pharmaceuticals sector are fortifying their moats with emerging immuno-oncology drugs.
Navigating the care maze can be overwhelming; understanding the lingo can help.
We take a numerical look through this week's Morningstar research. Plus, our most popular articles and videos for the week ended Aug. 18.
A new distribution model expands sales channels while freeing up resources for investment.
Revisiting 1999’s best-seller.
There were signs of growth at Target and Wal-Mart, but both firms are investing heavily to get it.
Nuclear operators in the U.S. have strong safety records and help utilities lower their carbon emissions, but the risk of a catastrophic accident remains.
The current approach to levying fees is outmoded and in need of change.
These financial planning terms sound so similar--or are so similar conceptually--that they're ripe for misuse.
BlackRock and T. Rowe Price remain our top picks in the space.
These funds could be well positioned to outperform when growth stocks take a back seat to steadier fare.
Let's look at the argument that indexers fail with corporate governance.